Table 2.
Parameter used in the base-case
| Type of parameter | Base Case value | References |
|---|---|---|
| Demographics | ||
| Population | 60,795,612 | [18] |
| Male in the health plan (% of total) | 48.5% | [17] |
| Paediatric in the health plan (% of total) | 11.9% | [17] |
| Annual population growth | 0.5% | [18] |
| Paediatric weight (Kg) | 18.5 | [21] |
| Adult weight (Kg) | 70.6 | [22] |
| Epidemiology | ||
| HA prevalence in male | 12.7 per 100,000 | [16] |
| Severity distribution of the disease | ||
| Mild | 39.7% | [16] |
| Moderate | 14.1% | |
| Severe | 46.2% | |
| Patients without inhibitors | ||
| Mild | 99.1% | [16] |
| Moderate | 96.3% | |
| Severe | 81.6% | |
| Treatment regimen among adults | ||
| On demand | 42.8% | [16] |
| Prophylaxis | 55.2% | |
| Treatment regimen among paediatrics | ||
| On demand | 0% | Assumption based on the opinion of clinical experts |
| Prophylaxis | 100% | |
| Costs | ||
| rFVIIIFc unit cost (€/IU) | 0.72 | [25] |
| Advate® unit cost (€/IU) | 0.65 | [25] |
| Kogenate® unit cost (€/IU) | 0.69 | [25] |
| Refacto® unit cost (€/IU) | 0.69 | [25] |
| Helixate® unit cost (€/IU) | 0.69 | [25] |
| Recombinate® unit cost (€/IU) | 0.60 | [25] |
| Plasma-derived unit cost (€/IU) | 0.60 | [25] |